Health TrialsbyHealthPanel

Investigating the Bioavailability of Broccoli Extract Supplements

ConditionDiet, Healthy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorOregon State University

About this trial

The goal of this clinical trial is to compare how much glucoraphanin and sulforaphane from 3 different versions of broccoli extract supplements is absorbed into the body and excreted in urine. This study involves generally healthy adults age 18-60 years. The supplements contain glucoraphanin and myrosinase enzyme, both naturally occurring in cruciferous vegetables. Once ingested, glucoraphanin is converted to the bioactive compound sulforaphane, which is thought to have numerous health benefits, including cancer prevention.

Participants will:

* consume 3 different versions of broccoli extract supplements (glucoraphanin will range from 35-70 mg) * complete 3 separate 24 hour study cycles * submit blood and urine samples for 24 hours * follow diet restrictions (no cruciferous vegetables or condiments or phytochemical/herbal supplements for 1 week prior to and during each study cycle)

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Healthy adults, 18-60 years of age

Willing to stop taking herbal and phytochemical (plant-based extract or phytochemical) supplements for 1 week prior to and during each study cycle

Willing to stop cruciferous vegetable intake 1 week prior to and during each study cycle

Must be able to give written informed consent

Disqualifiers

Body Mass Index (BMI) <18.5 or >30.0 kg/m2

Tobacco use, including e-cigarettes, or smoking of any substance (e.g. cannabis) in the past three months

Pregnancy, breastfeeding, or planning to become pregnant before completing the study

Engaging in vigorous exercise more than 7 hours per week

Trial design

Design model

Crossover

Treatments tested in this trial

  • Avmacol Extra Strength with coating - 1 tablet

    Dietary supplement

    Participants will swallow by mouth 1 tablet Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)

  • Avmacol chewable wafer - 2 tablets

    Dietary supplement

    Participants will chew and swallow by mouth 2 wafers Avmacol chewable wafers (30 mg glucoraphanin per wafer)

  • Avmacol Extra Strength with coating - 2 tablets

    Dietary supplement

    Participants will swallow by mouth 2 tablets Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)

Treatment groups

12 Participants
are divided into 3 treatment groups
Group A: 35 mg glucoraphaninActive comparator 1 intervention
Group B: 60 mg glucoraphaninActive comparator 1 intervention
Group C: 70 mg glucoraphaninActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Urine sulforaphane

Change from baseline levels of sulforaphane in urine

Time frame
0, 2, 4, 8, and 24 hours
2

Urine sulforaphane metabolites

Change from baseline levels of sulforaphane in urine

Time frame
0, 2, 4, 8, and 24 hours
3

Plasma glucoraphanin

Change from baseline levels of plasma glucoraphanin

Time frame
0, 1, 2, 4, 8, and 24 hours
4

Plasma sulforaphane

Change from baseline levels of plasma sulforaphane

Time frame
0, 1, 2, 4, 8, and 24 hours

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Oregon State University

Lead sponsor

Source ClinicalTrials.gov
Apply now